John G. Aunins, Ph.D.
John Aunins is the Executive Vice President of Bioprocess & Manufacturing and the Chief Technology Officer of Seres. He has more than 26 years of experience in the biotechnology industry, with a focus in bioprocess development, manufacturing support, and project leadership. Prior to joining Seres, he led process and product development teams at Merck Research Laboratories for Vaqta®, Varivax®, Zostavax®, ProQuad®, Rotateq®, and Gardasil®. The Vaqta and Gardasil process teams were awarded with ACS Industrial Biotechnology Awards for innovation, contribution to bioengineering, and societal impact. Dr Aunins is a Fellow of the American Institute for Medical and Biological Engineering and was recently awarded with D.I.C Wang Award for Excellence in Biochemical Engineering. He has authored over 50 articles and book chapters, and has chaired five international conferences in vaccines and bioprocess technology. Dr. Aunins earned his Ph.D. in chemical engineering from MIT, in 1989, under Professor Daniel I.C. Wang. Dr John Aunins is also visiting Professor at ITQB NOVA and member of iBET’s Scientific Advisory Board.
Barry C. Buckland, Ph.D.
Barry Buckland has been the CEO of BiologicB LLC since 2009 and serves as a Technical Advisor at Hilleman Laboratories. He served as Head of BioProcess Development at the Protein Sciences Corporation. His career in the Pharma industry includes his leadership of Merck’s bioprocess R&D Group. He is an experienced expert for the Development of Biologics with a special focus on vaccines and therapeutic proteins. Dr. Buckland was elected as Fellow in the UCL in 1998 and member of US National Academy of Engineering in 1997.
Clive Wood, Ph.D.
Clive Wood is Corporate Senior Vice President and Head of Research at Boehringer Ingelheim, since 2014. Previously, he was Head of Global Biologics and Senior Vice President at Bayer Healthcare, from 2009 to 2014. He is a top senior scientist with extensive experience in research and development of biopharmaceuticals. He has worked in several pharmaceutical companies, and has also close ties with the University. He is Adjunct Professor at the School of Medicine of Boston University and has a long list of patents and publications in high ranking scientific journals.
Günter Jagschies, Ph.D.
Günter Jagschies collaborates with GE Healthcare Life Sciences for more than 30 years and has held senior management positions in Business and R&D functions. Günter is co-author of “Process Chromatography”, and co-editor of “Development of Therapeutic Monoclonal Antibody Products”, a review and analysis of the Chemistry, Manufacturing, and Control (CMC) activities. In 2012, Günter received the "Thought Leader of the Decade" award in the field of downstream processing from Bioprocessing International. He co-chaired the 2016 “Recovery of Biological Products” conference (RXVII), a key event in downstream science and technology, and he is co-chair of the “BioProcessing Asia” conference series (BPA) held for the third time in Nov 2018. Günter is based near Freiburg, Germany.
Hitto Kaufmann, Ph.D.
Dr. Hitto Kaufmann is currently Senior Vice President and Chief Scientific Officer of Pieris Pharmaceuticals and Vice Chairman of the European Society of Animal Cell Technology. Dr. Kaufmann has over 20 years of experience in research, development and manufacturing of therapeutic biological entities. Prior to joining Pieris, Dr. Kaufmann held several executive positions at Sanofi and Boehringer Ingelheim. Dr. Kaufmann obtained his Ph.D. in Natural Science, at the Swiss Federal Institute of Technology in Zurich and a Master of Science degree in Biotechnology from the Technical University of Braunschweig and The Scripps Research Institute.
Chetan Goudar, Ph.D.
Chetan T. Goudar is a Vice President of Process Development at Amgen Inc. and leads the Attribute Sciences Function. His team generates attribute understanding across molecules in Amgen’s diverse pipeline and develops methods to test and control the attributes enabling progression of molecules from Discovery Research through regulatory approval and ultimately to patients. In Chetan’s prior roles at Amgen, his teams were engaged in developing drug substance processes across both synthetic and biologic modalities. Prior to joining Amgen in 2012, Chetan spent 13 years at Bayer HealthCare’s Process Development group in Berkeley. He is a recipient of the ACS BIOT and the Biochemical Engineering Journal young investigator awards and earned a Ph.D. in Chemical & Biological Engineering with Professor Jamie Piret at the University of British Columbia.